Everything below concerns HGF/c-Met. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
=== Crystal structure === In 2019, Chadeayne and colleagues solved the crystal structure of the fumarate salt of 4-HO-DPT. The authors describe the structure as follows: "The asymmetric unit contains one 4-HO-DPT cation, protonated at the dipropylamine N atom. There are also two independent water molecules, and half of a fumarate ion present."
25 October – 485 people affiliated with the environmental group Bream Bay Guardians build sand sculptures to protest against a fast-tracked sand mining proposal in Bream Bay. 26 October: Police arrest an 18-year old Dunedin man in relation to a bomb threat against the Wellington Islamic Centre in Kilbirnie. Health NZ confirms a measles case at Wellington Girls' College. Four staff and 60 students are identified as possible contacts of the patient. 27 October: Two new measles cases are reported in Wellington, bringing the total number of cases to 10. One case were linked to international travel while seven were linked to a "high-risk exposure event" on a Bluebridge ferry on 3 October. Health NZ identifies several hundred close contacts at Wellington College. Waatea News reports that Te Pāti Māori members had voted to recommend the suspension of MP Mariameno Kapa-Kingi and that the Te Tai Tokerau electorate executive be "reset" at a meeting on 23 October. The New Zealand Government contributes NZ$150,000 to mayoral relief funds in Southland and Clutha District to assist with post-windstorm damage. Chinese citizens transiting through New Zealand become eligible for the New Zealand Electronic Travel Authority (NZETA). 28 October: The Labour Party unveils its capital gains tax policy to fund doctors' visits. Education Minister Erica Stanford releases the Government's full draft curriculum for Years 0–10 students for consultation. A power outage at a waste treatment plant in Warkworth contaminates oyster farms in the Mahurangi River.
Despite its modern (Pharmacopoeia specified) standard structure, storage stability, potency, purity, and unit strength, with its narrow therapeutic index — i.e., difference between its minimum effective dose (MED) and toxic dose (TD) — and, as well, the small difference between its toxic dose and its lethal dose (LD), insulin remains a dangerous, high-alert medication (HAM).
== Public debate and criticisms == The plan to build the integrated resorts was subject to considerable debate among Singaporeans even until 2014. Several groups, especially those belonging to religious communities as well as social workers, openly expressed their disapproval of the casinos. Concerns were raised about the negative social impact of casino gambling, citing worries that the casinos could encourage more gambling and increase the risk of compulsive gambling. Activist groups argued that a casino could also lead to undesirable activities often associated with gambling, including money laundering, loan sharks or even organized crime. Lee acknowledged the downsides of having integrated resorts and the concerns expressed by the public. He promised that there would be safeguards to limit the social impact of casino gambling. He stated there would be restrictions on the admission of local people into the casinos. Lee announced a steep entrance fee of S$100 per entry or S$2,000 per year (increased to $150 per entry or $3,000 per year on 4 April 2019) and a system of exclusions for all Singaporeans. In addition, the casinos would not be allowed to extend credit to the local population who are not premium players. Premium players are players who opened a deposit account with the casino and has a credit balance of at least SGD $100,000. The six-month consultative period gave the opportunity for many sections of the population to voice their opposition to the casinos, including a petition hat attracted tens of thousands of signatures.
== Signs and symptoms == Sweat contributes to body odor when it is metabolized by bacteria on the skin. Medications that are used for other treatments and diet also affect odor. Some medical conditions, such as kidney failure and diabetic ketoacidosis, can also affect sweat odor.
Sources: en.wikipedia.org
There is also evidence that patients with a family history of Parkinson's or a genetic predisposition to the disease are more likely to develop the drug induced form of this disease as a result of cinnarizine treatment. In addition to antagonizing D2 receptors, treatment with cinnarizine leads to reduced presynaptic dopamine and serotonin, as well as alterations in vesicular transport of dopamine. Chronic treatment with cinnarizine builds the drug concentrations high enough that they interfere with the proton electrochemical gradient necessary for packaging dopamine into vesicles. Cinnarizine, pKa = 7.4, acts as a protonophore, which prevents the MgATP-dependent production of the electrochemical gradient crucial to the transport and storage of dopamine into vesicles, and thereby lowers the levels of dopamine in the basal ganglia neurons and leads to the Parkinson's symptoms. Several cases of pediatric and adult cinnarizine overdose have been reported, with effects including a range of symptoms such as somnolence, coma, vomiting, hypotonia, stupor, and convulsions. The cognitive complications likely result from the antihistaminic effects of cinnarizine, while the motor effects are a product of the antidopaminergic properties. In cases of overdose, the patient should be brought to and observed in a hospital for potential neurological complications.
CH2=CHCH2Cl + NaOH → CH2=CHCH2OH + NaCl Allyl alcohol can also be made by the rearrangement of propylene oxide, a reaction that is catalyzed by potassium alum at high temperature. The advantage of this method relative to the allyl chloride route is that it does not generate salt. Also avoiding chloride-containing intermediates is the "acetoxylation" of propylene to allyl acetate:
=== Differentiation from other species === Joshi et al. have used fluorescent microscopy and gas chromatography to distinguish the species, while Lederer et al. employed thin layer chromatography with HPLC-MS/MS.
The lack of organization structure has led to project cancellations, as it can be difficult to convince other employees to work on them. In 2020, Valve acknowledged that this made it difficult to gather momentum and had slowed its output during the 2010s. Its VR projects and Half-Life: Alyx became a turning point, setting short-term studio-wide goals to focus the company. According to Walker, "We sort of had to collectively admit we were wrong on the premise that you will be happiest if you work on something you personally want to work on the most." In January 2023, People Make Games released a report on Valve's corporate structure and culture, based on interviews with several current and former employees. They found that Valve's flat structure and stack-ranking compensation system created a poor release record and a lack of employee diversity. In 2024, Forbes estimated that Newell owned 50.1% of Valve, with the rest owned by employees. As part of Wolfire Games' lawsuit over Steam policies, case documents revealed details related to Valve's employee structure. Valve had 60 employees in 2003 and had approximately 350 employees between 2012 and 2021. Employees are categorized into administration, game development, Steam development and (from 2011) hardware development.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.